DTC Risk Information Placement Can Affect Fair Balance, Academic Tells FDA
Executive Summary
Direct-to-consumer ads need to better reflect the effect of risk information placement on patient comprehension of a drug's risk-benefit profile, a Duke University professor told FDA during a public meeting on DTC advertising in Washington, D.C. Sept. 22
You may also be interested in...
Pfizer DTC Comments Prescribe Limited Risk Info, Reliance On Physicians
Risk information in direct-to-consumer ads should be designed to prompt more patient-physician dialogue, Pfizer suggested in comments to FDA
Pfizer DTC Comments Prescribe Limited Risk Info, Reliance On Physicians
Risk information in direct-to-consumer ads should be designed to prompt more patient-physician dialogue, Pfizer suggested in comments to FDA
FDA Invites Manufacturers, Ad Agencies To Discuss DTC Ad Designs
FDA would like to consult with pharmaceutical companies and their advertising agencies early on in the development of direct-to-consumer advertising campaigns